[go: up one dir, main page]

BRPI0820162A2 - composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids - Google Patents

composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids

Info

Publication number
BRPI0820162A2
BRPI0820162A2 BRPI0820162A BRPI0820162A BRPI0820162A2 BR PI0820162 A2 BRPI0820162 A2 BR PI0820162A2 BR PI0820162 A BRPI0820162 A BR PI0820162A BR PI0820162 A BRPI0820162 A BR PI0820162A BR PI0820162 A2 BRPI0820162 A2 BR PI0820162A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
onset
aids
delay
Prior art date
Application number
BRPI0820162A
Other languages
English (en)
Inventor
T Sisko John
Anthony Neville
Gomez Robert
Tynebor Robert
M Jolly Samson
J Tucker Thomas
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI0820162A2 publication Critical patent/BRPI0820162A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BRPI0820162A 2007-11-20 2008-11-14 composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids BRPI0820162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US376907P 2007-11-20 2007-11-20
PCT/US2008/012774 WO2009067166A2 (en) 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0820162A2 true BRPI0820162A2 (pt) 2019-09-24

Family

ID=40336474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820162A BRPI0820162A2 (pt) 2007-11-20 2008-11-14 composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids

Country Status (12)

Country Link
US (1) US8404856B2 (pt)
EP (1) EP2222661B1 (pt)
JP (1) JP5539216B2 (pt)
KR (1) KR20100088142A (pt)
CN (1) CN101952274A (pt)
AU (1) AU2008326784B2 (pt)
BR (1) BRPI0820162A2 (pt)
CA (1) CA2705834A1 (pt)
IL (1) IL205386A0 (pt)
MX (1) MX2010005483A (pt)
RU (1) RU2010125220A (pt)
WO (1) WO2009067166A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026075A1 (en) * 2008-09-04 2010-03-11 F. Hoffmann-La Roche Ag Pyridine derivatives as inhibitors of hiv-i reverse transcriptase
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
US20130040914A1 (en) * 2010-04-08 2013-02-14 Samson M. Jolly Prodrugs of an hiv reverse transcriptase inhibitor
EP2900240B1 (en) * 2012-09-26 2020-01-08 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CA2892919A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
MX367369B (es) * 2013-12-04 2019-08-16 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
LT3125894T (lt) * 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
US10953029B2 (en) * 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
MA54549A (fr) 2018-12-18 2022-03-30 Merck Sharp & Dohme Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
AU2020279954B2 (en) * 2019-05-22 2025-11-13 Merck Sharp & Dohme Llc Pyridinone derivatives as selective cytotoxic agents against HIV infected cells
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) * 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
CN1303378A (zh) 1998-04-27 2001-07-11 国家科研中心 3－(氨基－或氨基烷基)吡啶酮衍生物和它们在hiv相关疾病治疗中的用途
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
WO2001056990A2 (en) * 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
ES2242771T5 (es) 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como inhibidores de proteína quinasas.
EP1318995B1 (en) * 2000-09-19 2006-03-08 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4164031B2 (ja) * 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
NZ541902A (en) * 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
US20050014774A1 (en) * 2003-04-28 2005-01-20 Richard Storer Oxo-pyrimidine compounds
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CA2625047A1 (en) * 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ATE425138T1 (de) 2005-10-19 2009-03-15 Hoffmann La Roche N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2008098143A2 (en) * 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
EP2222661B1 (en) 2016-04-20
KR20100088142A (ko) 2010-08-06
JP2011503230A (ja) 2011-01-27
CA2705834A1 (en) 2009-05-28
AU2008326784A1 (en) 2009-05-28
RU2010125220A (ru) 2011-12-27
IL205386A0 (en) 2010-12-30
MX2010005483A (es) 2010-06-11
JP5539216B2 (ja) 2014-07-02
AU2008326784B2 (en) 2014-04-24
WO2009067166A2 (en) 2009-05-28
CN101952274A (zh) 2011-01-19
US20100256181A1 (en) 2010-10-07
WO2009067166A3 (en) 2009-07-16
US8404856B2 (en) 2013-03-26
EP2222661A2 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
BRPI0820162A2 (pt) composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids
WO2008115281A3 (en) Compounds for treating viral infections
IL269370B (en) Chemicals, preparations and methods for the treatment and prevention of orthopoxvirus infections and related diseases
WO2008127364A3 (en) Antiviral compounds and use thereof
IL253038A0 (en) Preparations and methods for the treatment or prevention of infections. my voice
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BRPI0806686A2 (pt) Compostos e seus usos, métodos de tratamento ou prevenção, composições farmacêuticas e composto e solvato cristalinos
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
PT2109602E (pt) Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias
BRPI1012951A2 (pt) "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
BR112013013435A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto.
BRPI0813001A2 (pt) composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica
EP1868628A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING POCKET VIRUS INFECTIONS
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
BRPI0814300A2 (pt) Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI0811849A2 (pt) Composto, composição farmacêutica, e, métodos para preparar o compost e para tratar doenças ou condições mediadas por ccr1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.